Surfactant Inadvertent Loss Using Feeding Catheters or Endotracheal Tubes

Abstract

Objective Surfactant has been administered through endotracheal tubes and also under spontaneous breathing using feeding catheters. We asked if different tube diameters and temperature may affect the amount of surfactant effectively delivered to the lungs.

Design Bench study using high-accuracy, legal balance and tube/catheters of different diameters. We injected 200 mg of poractant alfa into the tubes followed by air boluses. Experiments were performed in triplicate, both at room temperature and at 37°C. Surfactant and phospholipid remaining in the tube were calculated.

Results Surfactant lost into thin catheters (11 ± 0.4%) was more than that in endotracheal tubes (2-mm diameter: 3.6 ± 1.4%; 2.5-mm diameter: 3.7 ± 0.2%; 3-mm diameter: 5.2 ± 0.4%; p < 0.001 at post hoc test in each comparison against the thin catheter). Similar findings were found at 37°C (2-mm tube: 3.4 ± 0.4%; 2.5-mm tube: 3.8 ± 0.2%; 3-mm tube: 3.6 ± 0.4%; feeding tube: 11.5 ± 0.6%; p < 0.001 as above). In terms of lost phospholipids, 23 ± 0.8 mg were lost in the feeding tubes; 7.2 ± 2.9 mg (2-mm diameter), 7.4 ± 0.4 mg (2.5-mm diameter), and 10.3 ± 0.9 mg (3-mm diameter) of phospholipids remained in endotracheal tubes (p < 0.001 in each comparison against the feeding tube).

Conclusions Surfactant loss using thin catheters is around two to three times higher than using common endotracheal tubes; on average, 20 mg of phospholipids (11% of the administered dose) are lost. These data may be useful to refine surfactant dosing.

Keywords

surfactant - loss - tube

• References

• 1 De Luca D, Cogo P, Zecca E , et al. Intrapulmonary drug administration in neonatal and paediatric critical care: a comprehensive review. Eur Respir J 2011; 37: 678-689
• 2 Sweet DG, Carnielli V, Greisen G , et al; European Association of Perinatal Medicine. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants—2010 update. Neonatology 2010; 97: 402-417
• 3 Verder H, Robertson B, Greisen G , et al; Danish-Swedish Multicenter Study Group. Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. N Engl J Med 1994; 331: 1051-1055
• 4 Göpel W, Kribs A, Ziegler A , et al; German Neonatal Network. Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial. Lancet 2011; 378: 1627-1634
• 5 Kribs A, Pillekamp F, Hünseler C, Vierzig A, Roth B. Early administration of surfactant in spontaneous breathing with nCPAP: feasibility and outcome in extremely premature infants (postmenstrual age </= 27 weeks). Paediatr Anaesth 2007; 17: 364-369
• 6 Cools F. A new method of surfactant administration in preterm infants. Lancet 2011; 378: 1607-1608
• 7 Willson DF, Notter RH. The future of exogenous surfactant therapy. Respir Care 2011; 56: 1369-1386 , discussion 1386–1388
• 8 Robertson B, Enhörning G, Malmquist E. Quantitative determination of pulmonary surfactant with pulsating bubble. Scand J Clin Lab Invest 1972; 29: 45-49